En la neoplasia intraepitelial cervical de alto grado | 14 JUL 18

Efecto del cribado con la prueba del VPH frente a la prueba de citología

Las mujeres basales con VPH negativo tuvieron una incidencia acumulativa significativamente menor de neoplasia intraepitelial cervical de alto grado a los 48 meses

Autor/a: Gina Suzanne Ogilvie, MD, FCFP, DrPH1,2; Dirk van Niekerk, MB Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 MonthsThe HPV FOCAL Randomized Clinical Trial

INDICE: 1. Página 1 | 2. Página 1

Página 1

Arbyn M, Rebolj M, De Kok IM, et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer. 2009;45(15):2671-2678. doi:10.1016/j.ejca.2009.07.016PubMedGoogle ScholarCrossref
American Society of Clinical Oncology. Cervical cancer: statistics. Cancer.net. http://www.cancer.net/cancer-types/cervical-cancer/statistics. Published July 2017. Accessed April 14, 2018.
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-FPubMed
Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519-527. doi:10.1093/cid/ciw354PubMedGoogle ScholarCrossref
Jeronimo J, Castle PE, Temin S, et al. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. J Glob Oncol. 2016;3(5):635-657. doi:10.1200/JGO.2016.006577PubMedGoogle ScholarCrossref
Murphy J, Kennedy EB, Dunn S, et al. HPV testing in primary cervical screening: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2012;34(5):443-452. doi:10.1016/S1701-2163(16)35241-0PubMedGoogle ScholarCrossref
Ronco G, Dillner J, Elfström KM, et al; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-532. doi:10.1016/S0140-6736(13)62218-7PubMedGoogle ScholarCrossref
Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178-182. doi:10.1016/j.ygyno.2014.12.022PubMedGoogle ScholarCrossref
Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force: Evidence Syntheses, No. 86s. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
Moyer VA; US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2013;158(11):852]. Ann Intern Med. 2012;156(12):880-891, W312. doi:10.7326/0003-4819-156-12-201206190-00424PubMedGoogle ScholarCrossref
Coldman AJ, Gondara L, Smith LW, et al. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. Br J Cancer. 2016;115(12):1487-1494. doi:10.1038/bjc.2016.368PubMedGoogle ScholarCrossref
Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111. doi:10.1186/1471-2407-10-111PubMedGoogle ScholarCrossref
Ogilvie GS, Krajden M, van Niekerk DJ, et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial: the HPV FOCAL Study. Br J Cancer. 2012;107(12):1917-1924. doi:10.1038/bjc.2012.489PubMedGoogle ScholarCrossref
Ogilvie GS, Krajden M, van Niekerk